PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1067.86%
EBIT growth of 1067.86% while Healthcare median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
39.05%
Operating income growth of 39.05% while Healthcare median is zero. Walter Schloss might see a modest advantage that can expand.
24.67%
Net income growth of 24.67% while Healthcare median is zero. Walter Schloss might see potential if moderate gains can keep rising.
25.26%
EPS growth of 25.26% while Healthcare median is zero. Walter Schloss might see a slight edge that could compound over time.
25.26%
Diluted EPS growth of 25.26% while Healthcare median is zero. Walter Schloss might see a slight edge that could improve over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.67%
Negative OCF growth while Healthcare median is 0.00%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-25.67%
Negative FCF growth while Healthcare median is 0.00%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.29%
Negative 10Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-10.29%
Negative 5Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
-46.03%
Negative 3Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.
68.39%
Net income/share CAGR exceeding 1.5x Healthcare median of 14.05% over a decade. Joel Greenblatt might see a standout compounder of earnings.
68.39%
5Y net income/share CAGR > 1.5x Healthcare median of 7.45%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
65.23%
3Y net income/share CAGR > 1.5x Healthcare median of 8.99%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
-358.21%
Negative 10Y equity/share growth while Healthcare median is 0.00%. Seth Klarman would see a firm-specific weakness if peers still expand equity.
-358.21%
Negative 5Y equity/share growth while Healthcare median is 0.00%. Seth Klarman suspects firm-specific weaknesses if peers grow equity mid-term.
-14.02%
Negative 3Y equity/share growth while Healthcare median is 0.00%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-3.24%
Negative BV/share change while Healthcare median is 0.00%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
8.21%
Debt growth of 8.21% while Healthcare median is zero. Walter Schloss might see a modest difference that matters if interest coverage is tight.
No Data
No Data available this quarter, please select a different quarter.
-39.30%
SG&A decline while Healthcare grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.